On October 1, 2025, Navidea Biopharmaceuticals filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware. This move indicates the company is aiming to restructure its finances amidst ongoing operational and financial difficulties.
According to records from PacerMonitor, Navidea Biopharmaceuticals, located at 4100 Horizons Drive, Suite 205, Columbus, OH 43220, has engaged Joseph C. Barsalona II of Pashman Stein Walder Hayden, P.C. to represent its case. The company has reported having between 100 and 199 creditors, with assets estimated between $1 million and $10 million, and liabilities ranging from $10 million to $50 million. This case has been designated as a Subchapter V small business filing, which allows for a streamlined restructuring process. The court is set to schedule further filings and meetings to discuss the company’s path forward.
Company Overview and Challenges
Founded as a clinical-stage biopharmaceutical entity, Navidea focuses on developing precision immunodiagnostics and immunotherapeutics. The firm utilizes its proprietary Manocept platform, which targets disease-related macrophages, aiming to enhance diagnostic accuracy and facilitate advanced treatment options. Its research initiatives concentrate on significant health issues such as cancer, autoimmune disorders, and inflammatory diseases.
Historically, Navidea has engaged in strategic partnerships that have bolstered its financial standing, including the notable 2017 sale of the North American rights to Lymphoseek, which provided substantial upfront revenue. Despite these successes, the company is currently facing critical financial pressures, including challenges with regulatory compliance and liquidity.
Through the Chapter 11 process, Navidea seeks to navigate these difficulties by restructuring its operations and negotiating with creditors. The outcome of this restructuring will depend on court approval and the company’s ability to effectively manage its financial obligations while continuing its commitment to advancing biopharmaceutical innovations.
As the situation unfolds, stakeholders will be closely monitoring Navidea’s progress in addressing its financial and operational hurdles while striving to maintain its position at the forefront of immunology-based medical solutions.
